Contact for press

You can contact us by:

Marián Ariza Communication Department.

Media Kit

Follow us on:

Keep up-to-date on the latest at the Abengoa website:

November

Telvent participates in the "Mind: A Multidisciplinary Approach to Alzheimer's Disease" research project, within the Cenit program framework

November 11, 2008

November 11, 2008. - Telvent (NASDAQ: TLVT), the IT company for a sustainable and secure world, announced today its participation in the “Mind: A Multidisciplinary Approach to Alzheimer’s Disease” research project, launched by the Ministry of Science and Innovation within the framework of the Cenit program. The project seeks to define potential markers enabling early diagnosis of Alzheimer’s disease and other kinds of degenerative dementia.

The project involves analysis of the paradigms defined in medical practice and research with respect to Alzheimer’s disease, and will attempt to provide a globalized and parameterized perspective of the environment in which the lives of patients and their caretakers are led. The aim of the project is to gain an overall view that will bring together all of the areas involved in the study of this disease and permit research and innovation in treatment options, as well as enhance the quality of life of both patients and their families.

“Mind: A Multidisciplinary Approach to Alzheimer’s Disease” is focused on research and integration of the knowledge derived from numerous biotechnological areas, especially medical imaging and omics (genomics, metabolomics and spliceomics, among others), as well as tutoring in assistance procedures through advanced management of interdisciplinary knowledge.

Telvent has embraced a deep commitment to this project, which, headed up by Eresa, enjoys the collaboration of important companies such as Neuropharma, Sistemas Genómicos, Bilbomática, Oryzon, Onco-Vision, Neuron BPh, Noraybio, PET Technological Institute, Valentia Biopharma, Gerozerlan and eMédica. All of the companies that make up the consortium in turn hold subcontracts with diverse public research institutions (PRIs). These partners and their PRIs are located in various autonomous communities, thereby giving a multi-territorial dimension to the Mind project.

All of the companies involved in the project have expertise in the study of Alzheimer’s disease, and are supported by lines of research contrasted through diagnostic imaging, the development of new pharmaceuticals and information technologies at the service of medical practice, all in line with the goals set for Mind.

Telvent is a participant in numerous public R&D&i projects involving European, national or regional initiatives. The company is currently carrying out significant research and innovation activity in the Healthcare segment, where worth highlighting is the company’s participation in the PMAI (Medical Imaging) projects, eQECM (Intelligent Operating Room), Nuadu (Teleassistance Platform), SIMFO (S.I. Forensic Multimedia), PPC-RFID (Traceability through RFID technology), AmIvital (Technologies for Health and Well-Being in the AAL-Ambient Assisted Living) segment, for which it was awarded the 2007 National Prize for the best R&D&i business project in the Healthcare field (SEIS-Spanish Society of Healthcare Computer Technology) and the Andalusian Prize for the best R&D&i Healthcare project, for its PMAI initiative.

About Telvent

Telvent (NASDAQ: TLVT) is a unique global company listed on the NASDAQ Stock Exchange and a component of the CleanTech IndexTM —the first, and only, stock market index of leading clean technology ("cleantech") companies.

Telvent, the IT Company for a sustainable and secure world, specializes in high-value-added products, services and integrated solutions in the Energy, Transportation, Environmental and Public Administration industry segments, as well as Global Services. Its innovative technology and proven experience help ensure secure and efficient management of the operating and business processes of the world’s leading companies. (www.telvent.com)

Investor Relations Contact

Barbara Zubiria
Tel. +34 902 335599
Email: barbara.zubiria@telvent.com

Lucia Domville
Tel. +1 646 284 9416
Email: ldomville@hfgcg.com

Communication Contact

Patricia Malo de Molina
Tel. +34 954 93 71 11
Email: comunicacion@abengoa.com



© 2019 Abengoa. All rights reserved